PEG-IFN Plus Ribavirin Combination Therapy for Older Patients
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to analyze the efficacy and safety of a combination therapy of
pegylated interferon (PEG-IFN) alpha-2b plus ribavirin (RBV) for older Japanese patients
(≧65years old) infected with hepatitis C virus (HCV) compared with younger patients(< 65
years old).